Better AAV therapeutics

The promise of AAV gene therapy comes with an obligation to solve the complicated issue of supplying viral-based gene therapies on a global scale. AAV manufacturing is highly complex and historically inefficient with a cost of goods that pushes the purchase of therapeutics into the millions of dollars. We recognized this issue more than a decade ago and focused on creating robust, scalable manufacturing capabilities. The result was Pro10™ technology and joint ventures to create world-class GMP manufacturing facilities.

ViralGen logo

Clinical and commercial AAV manufacturing

Together with Columbus Venture Partners, AskBio operates Viralgen, a cGMP manufacturing facility. The Viralgen Vector Core uses our Pro10™ technology to manufacture AAV in a state-of-the-art facility for use in human gene therapy clinical trials. An expansion for high-volume commercial AAV manufacturing is currently underway. Viralgen offers what we believe is the most flexible, scalable AAV manufacturing system in the industry. 

We continue to invest in innovative AAV manufacturing as a partner in Viralgen, a focused CDMO organization. We continue to set the industry standard for scalable, reliable and efficient manufacturing to help drive down cost and expand patient access to life-changing therapies. 

AAVPlatform proven end-to-end capability results in technology to increase scale and lower costs of goods as well as translate into clinic faster, safer and with greater predictability.
AAVPlatform proven end-to-end capability results in technology to increase scale and lower costs of goods as well as translate into clinic faster, safer and with greater predictability.
TouchLight AAV logo

Doggybone™ DNA (dbDNA™) manufacturing

AskBio and Touchlight Genetics Ltd. (TGL) formed Touchlight AAV, to supply the rapidly expanding AAV market with proprietary doggybone™ DNA (dbDNA™). An alternative to traditional transfection DNA substrate and a critical starting material, we are setting new standards for synthetic DNA best practices. Our high-yield manufacturing process lowers cost, expedites production and increases safety without prokaryotic DNA sequences.

Synthetic dbDNA™

A synthetic bench-top process alternative to plasmid DNA.

 In response to the Governor's Executive Order, SCDOC has composed a quick reference of guidelines for determining whether your business is considered essential.
 In response to the Governor's Executive Order, SCDOC has composed a quick reference of guidelines for determining whether your business is considered essential.

Ask Jude

“We must ensure gene therapy can be equally accessible, even to those with ultra-rare diseases. Large-scale, efficient manufacturing of AAV product is critical.”

R. Jude Samulski, PhD
Chief Scientific Officer and Co-Founder